title: Bioresorbable vascular scaffolds in daily clinical practice: is the essential really invisible to the eyes?
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil. Electronic address: aabizaid@uol.com.br.
authors.forename: Alexandre
authors.initials: A
authors.lastname: Abizaid
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, Brazil.
authors.forename: J Ribamar
authors.initials: JR
authors.lastname: Costa
authors.affiliation: Harvard Medical School, Boston, Massachusetts.
authors.forename: C Michael
authors.initials: CM
authors.lastname: Gibson
mesh_terms: D003324:Coronary Artery Disease / Q000601:surgery*; D023903:Coronary Restenosis; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D000068338:Everolimus; D005260:Female; D006801:Humans; D008297:Male; D062645:Percutaneous Coronary Intervention; D011183:Postoperative Complications; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D000068338:Everolimus; C518022:umirolimus; D020123:Sirolimus
keywords: ABSORB; bioresorbable vascular scaffold; drug-eluting stents(s); randomized trial